Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia

Recently, several targeted agents have been developed for specific subsets of patients with acute myeloid leukaemia (AML), including midostaurin, the first FDA‐approved FLT3 inhibitor for newly diagnosed patients with FLT3 mutations. However, in the initial Phase I/II clinical trials, some patients...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Cell Mol Med
Hlavní autoři: Weisberg, Ellen, Meng, Chengcheng, Case, Abigail E., Tiv, Hong L., Gokhale, Prafulla C., Buhrlage, Sara J., Yang, Jing, Liu, Xiaoxi, Wang, Jinhua, Gray, Nathanael, Adamia, Sophia, Sattler, Martin, Stone, Richard, Griffin, James D.
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7077552/
https://ncbi.nlm.nih.gov/pubmed/31967735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14927
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky